On October 24, 2018 Nusano (previously known as Alpha Source Inc./Alpha Isotopes) reported that it has raised $41 million from investors, according to an Oct. 24 securities filing (Press release, Nusano, OCT 24, 2018, View Source [SID1234629349]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The developer of radioisotopes, also doing business as Alpha Isotopes, raised $41,464,543 during a seed round from 11 investors, according to a filing to the U.S. Securities and Exchange Commission.

Alpha Source launched as a limited liability corporation in 2007, was incorporated two years ago, according to the California Secretary of State.

It is now led by Dr. Howard Lewin, a cardiologist affiliated with Cedars-Sinai Medical Center and Ronald Reagan UCLA Medical Center.

The company has patented a new technology to create a range of radioisotopes to be used in medicine, Lewin said on his LinkedIn page.

Alpha Source can either make them at less cost than those currently being produced, he said. Or the company can create new radioisotopes once too costly to make that will expand the market and help develop radiopharmaceuticals for personalized cancer therapies.